The Third WHO Global Consultation on Organ Donation and Transplantation was an international policy meeting held in Madrid, Spain, from March 23 to 25, 2010. Its published theme, “Striving to Achieve Self-Sufficiency,” places the consultation within a global effort to expand and secure organ donation rather than allow preventable shortages to determine who receives transplantation. In the hepatitis C setting, that concern becomes sharply practical: the transplantation system must weigh the danger of transmitting infection against the consequences of discarding usable kidneys.

Setting and Purpose

The consultation is cited as a joint initiative of the World Health Organization, The Transplantation Society, and Organización Nacional de Trasplantes. Its subject was not limited to one disease or one national program; it addressed the broader organization of organ donation and transplantation and the pursuit of sufficient domestic or regional supply. That policy horizon matters for patients with end-stage renal disease, for whom remaining on dialysis carries a substantial health burden and for whom an available kidney may offer a better prospect than continued waiting.

The consultation’s emphasis on self-sufficiency also frames transplantation as a systems problem. The evidence describes prolonged waits for deceased-donor kidneys, with some areas of the United States approaching five to seven years. During such delays, candidates with active hepatitis C require repeated assessment because liver disease may progress while they remain on the waiting list. Organ policy therefore intersects with surveillance, referral, antiviral treatment, and the continuing judgment that a candidate remains suitable for kidney-alone transplantation.

Hepatitis C and Transplantation Policy

Hepatitis C infection is a major cause of chronic liver disease worldwide, with an estimated prevalence of about 3% in the global population and more than 170 million chronically infected people in earlier estimates. Its importance in transplantation extends beyond the liver. HCV-infected patients, including transplant recipients, have an increased risk of glomerular lesions and chronic kidney disease, and hepatitis C has been associated with poorer long-term graft and patient survival after kidney transplantation, as well as post-transplant diabetes, glomerulonephritis, proteinuria, and chronic allograft nephropathy.

The consultation’s self-sufficiency agenda therefore operates against a clinical dilemma. Treating hepatitis C before transplantation may reduce later complications, but interferon-based therapy is prolonged, toxic, not universally effective, and expensive; it may also require a patient to be removed from the waiting list during treatment. Interferon after kidney transplantation is generally avoided because it increases the risk of allograft dysfunction and rejection, except in life-threatening complications such as fibrosing cholestatic hepatitis. The most attractive timing for eradication is consequently before transplantation, yet that strategy can leave some HCV RNA-positive candidates without a practical route to treatment.

Screening, Staging, and Eligibility

The transplantation framework associated with this policy debate requires more than a simple antibody result. Candidates should be screened for anti-HCV antibody and, where appropriate, active viremia by nucleic acid testing. Patients with active infection require assessment of extrahepatic disease, including cryoglobulinemia-associated vasculitis, and evaluation of liver injury. Although noninvasive markers have been sought, liver biopsy remains the reference method for staging advanced liver disease in HCV-infected kidney transplant candidates.

The stakes rise when biopsy identifies cirrhosis. Established or decompensated cirrhosis generally warrants referral to a liver transplant team for consideration of combined liver-kidney transplantation rather than kidney-alone transplantation. For well-compensated cirrhosis, a consensus approach proposed using portal-hypertension criteria to distinguish candidates for combined transplantation from those who might proceed with a kidney alone. A wedge hepatic vein pressure below 10 mm Hg was proposed as a criterion for kidney-alone listing, while the clinical programs described also considered the absence of varices on endoscopy and a platelet count above 120,000 per microliter.

The evidence remains cautious because cirrhosis increases perioperative morbidity and mortality, susceptibility to infectious and metabolic complications, and the risk of inferior long-term survival. In one single-center series, only 26% of the small group of patients with pretransplant cirrhosis were alive ten years after transplantation. These figures reinforce the consultation’s larger message: self-sufficiency cannot mean indiscriminate expansion of transplantation; organ access must be paired with accurate classification of medical risk.

HCV-Positive Donors and the Cost of Scarcity

The policy problem is most visible in the use of kidneys from HCV-antibody-positive donors. Spanish center-based experiences showed that transplanting such kidneys into HCV-positive recipients did not completely prevent HCV transmission. The resulting recommendation was restrictive but not prohibitive: kidneys from HCV-positive donors should be offered only to candidates who are HCV RNA-positive and who have consented in advance to receive such an organ.

A decision analysis comparing four policies made the trade-off explicit. Under assumptions including a 2.4% prevalence of HCV antibodies among deceased donors, a 20% prevalence of HCV infection among dialysis patients, and transmission from HCV RNA-positive donor kidneys, unrestricted use would avoid organ loss but produce transmission and new infections. Universal rejection of HCV-positive donor organs would prevent transmission and new infection but discard 4.2% of organs. Restricting those kidneys to HCV-seropositive recipients would still leave a transmission risk of 2.4% and a new-infection risk of 0.5%. The most balanced strategy was to restrict use to recipients who were HCV RNA-positive before transplantation: the theoretical transmission risk remained 2.4%, but new infections and graft losses were projected at zero.

This calculation captures the ethical and clinical tension that the consultation’s pursuit of self-sufficiency brings into view. A kidney from an HCV-positive donor is not simply a contaminated object or a surplus resource. Its use can preserve an organ that might otherwise be lost, shorten the path from dialysis to transplantation for a patient already carrying the virus, and avoid exposing an HCV-negative recipient to a preventable infection. The safeguard is deliberate recipient selection and prior consent, not the blanket exclusion of every positive donor organ.

Consequences for Patients and the Transplant System

Kidney transplantation remains the best therapeutic strategy for many HCV-positive patients with end-stage renal disease because survival after transplantation is significantly better than survival while remaining on the waiting list. Yet HCV-positive recipients still have worse long-term graft and patient survival than HCV-negative recipients, so the policy cannot be judged by access alone. It must also account for post-transplant liver progression, graft complications, rejection risk, and the possibility of HCV-related renal disease in the allograft.

The consultation’s historical significance lies in the way it links organ supply to disciplined risk management. Self-sufficiency requires more kidneys, but safe expansion requires screening, biopsy-based liver staging, annual monitoring of candidates who remain viremic, confirmation of durable sustained virologic response after treatment, and referral when disease progresses. It also requires that patients who cannot tolerate, complete, or afford antiviral therapy are not automatically abandoned to dialysis when a carefully consented HCV-positive kidney could offer a better overall course.

In this evidence, the Madrid meeting is therefore less a single clinical intervention than a policy landmark. Its theme supplies the organizing principle for later recommendations: protect recipients, prevent new infections, respect informed choice, and do not waste organs when a controlled allocation strategy can convert infectious risk into an acceptable transplantation option.